Kanagawa, Japan, February 29th, 2024, – SCOHIA PHARMA Inc. (“SCOHIA”) announces that SCOHIA’s preclinical oral drug program, S-483, has been selected as one of the ‘FY2024 Support Programs for Orphan Drug Prior to Designation’ of the Japan Agency for Medical Research and Development (AMED), under which SCOHIA will receive funding from AMED to conduct further development of S-483 for 21-hydroxylase deficiency.
21-hydroxylase deficiency is a major cause of Congenital Adrenal Hyperplasia (CAH), a group of rare disorders that impair adrenal steroidogenesis and cortisol synthesis. This impairment leads to excessive adrenal androgen production, induced by increased pituitary secretion of adrenocorticotropic hormone (ACTH). Approximately 95% of CAH cases are due to this deficiency, which can cause serious complications in female infants, including atypical genitalia.
S-483 is an orally available drug candidate with a yet undisclosed mechanism of action. The AMED funding will be used to further advance the development of S-483.
About SCOHIA PHARMA, Inc.:
SCOHIA PHARMA, Inc. is a drug discovery company focused on the discovery and development of new treatments addressing unmet medical needs with a high level of expertise in endocrine, cardiovascular, renal, and metabolic systems. For more information about SCOHIA PHARMA, Inc., please visit https://www.scohia.com/eng/